Key Points {#FPar1}
==========

In patients originating from the Middle East and North Africa region, phenytoin metabolism was significantly decreased by genetic polymorphisms of the cytochrome P450 (CYP) 2C9 enzyme; the impacts of *CYP2C19* and multidrug resistance protein 1 C3435T polymorphisms were unclear.The impacts of genetic polymorphisms on clinical outcomes associated with phenytoin are not well described in the literature and warrant further investigation.

Introduction {#Sec1}
============

Since the discovery of its anticonvulsant properties in 1938 \[[@CR1]\], phenytoin has been widely used for both the acute management and chronic prevention of seizures \[[@CR2], [@CR3]\]. Its primary mechanism in treating and preventing seizures is through preferential binding to inactivated sodium channels, which inhibits neuronal generation of sustained high-frequency bursts of action potentials \[[@CR4]\]. Phenytoin has a narrow therapeutic index, with 40--80 µmol/L (10--20 mg/L) being the recommend therapeutic range; however, this is often difficult to achieve due to wide interpatient variability in dose response and concentrations achieved from a given dose, as well as the capacity-limited metabolism of phenytoin \[[@CR5], [@CR6]\].

Factors such as patient body size and composition, serum albumin levels, comorbid disease states, and drug--drug interactions have been shown to contribute to the interpatient variability of the effect of phenytoin. Additionally, genetic polymorphisms of enzymes and transporters targeting phenytoin pharmacokinetics have been recognized as a significant contributor to the exhibited interpatient variability \[[@CR5]--[@CR7]\]. Evidence linking the cytochrome P450 (CYP) 2C9 polymorphism to the concentration of phenytoin has led to the development of guidelines tailoring the initial dose of phenytoin based on the *CYP2C9* genotype \[[@CR7]--[@CR9]\]. Though not as well studied, there is evidence to suggest that polymorphisms of *CYP2C19* may also significantly impact the concentration of phenytoin and warrant dosage adjustments \[[@CR7], [@CR10]\]. Additional enzymes and drug transporters have been investigated, but the implications of these polymorphisms are not well established \[[@CR7], [@CR11]\].

Cited studies investigating the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of phenytoin have predominantly been conducted in patients of European, Indian, and East Asian origin; however, few studies have been conducted in patients originating from the Middle East and North Africa (MENA) region \[[@CR11], [@CR12]\]. As a result of migration and significant admixture of European, Asian, and African populations dating back over thousands of years, the MENA region has a unique genetic diversity, with great variability in minor allelic frequencies (MAF) of genetic polymorphisms \[[@CR13]--[@CR15]\]. Even within the MENA region itself, there is great diversity. For example, while populations of Arabic and Iranian origin have both European and African ancestry, those of Iranian origin also have a significant level of Asian admixture \[[@CR15]\]. Furthermore, as a result of consanguinity, some countries within the MENA region may exhibit relatively less genetic diversity \[[@CR15]\]. Therefore, results of previous studies conducted in patients of different ethnic origins are not readily generalizable, and a focused review of the literature addressing genetic polymorphisms and the associated implications regarding phenytoin in individuals originating from the MENA region is warranted.

The primary objective of this systematic review was to evaluate the impact of genetic polymorphisms on phenytoin pharmacokinetics, specifically in populations originating from the MENA region. Secondary objectives were to evaluate the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy, as well as to characterize the genotypic and allelic frequencies of each polymorphism identified in the primary search within the MENA region.

Methods {#Sec2}
=======

Search Strategy {#Sec3}
---------------

A comprehensive search of the MEDLINE (1946--May 2017), EMBASE (1974--May 2017), Pharmacogenomics Knowledge Base (PharmGKB), and Public Health Genomics Knowledge Base (PHGKB) online databases was conducted to identify existing literature addressing the primary research question. An example of the search terms and Boolean connectors used in MEDLINE is outlined in the Appendix, and is reflective of the search strategy used in EMBASE. References of pertinent studies were also searched manually to identify additional studies not identified in the electronic search. For each polymorphism assessed in the studies that met the inclusion criteria, a secondary search was conducted to identify the reported variant MAF, specifically within the MENA region.

Selection of Studies {#Sec4}
--------------------

Studies were eligible for inclusion if participants originated from the MENA region, received at least one dose of phenytoin with a subsequent pharmacokinetic analysis, and were genotyped for a polymorphism that may impact phenytoin pharmacokinetics. Although understanding the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy was a secondary objective of this review, eligible studies were not required to report on clinical outcomes. Two reviewers (RD, KW) screened potentially relevant studies by title and abstract, and then by full text to exclude any studies that did not fulfill the inclusion criteria. For the review regarding variant MAF, studies were included if participants originated from the MENA region and were genotyped for one or more of the polymorphisms assessed in the primary review.

Data Extraction and Management {#Sec5}
------------------------------

Data from each included study were extracted and tabulated. Extracted data included: author, year of publication, study population (country of origin, practice setting, inclusion and exclusion criteria), sample size, study design, genetic polymorphism(s) assessed, phenytoin dosing, assay methods for phenytoin serum concentrations and genotyping, MAF of the genetic polymorphism(s), as well as final study results. For studies also including participants from outside of the MENA region, only data regarding participants who originated from the MENA region were extracted.

Similarly, for studies included in the review of variant MAF, the following data were extracted: author, country of origin, sample size, genetic polymorphism(s) assessed, as well as the computed genotypic and allelic frequencies. If studies eligible for inclusion also reported data from participants originating outside of the MENA region, only data on participants who originated from the MENA region were extracted.

Quality Assessment {#Sec6}
------------------

The quality of each study included in the primary review was assessed by two reviewers (RD, KW) using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, from the National Institutes of Health, National Heart, Lung, and Blood Institute \[[@CR16]\].

Data Synthesis {#Sec7}
--------------

Data extracted from the included studies were assessed descriptively. If two or more studies reported the genotypic or allelic frequency of a given polymorphism, data from all studies were reported. The highest and lowest frequencies extracted for each polymorphism were assessed to estimate variants' MAF range within the MENA region.

Results {#Sec8}
=======

Study Selection {#Sec9}
---------------

A total of five studies fulfilled the inclusion criteria for this review, as depicted in Fig. [1](#Fig1){ref-type="fig"}. Of the 30 articles screened for eligibility, ten were excluded for subjects not originating from the MENA region \[[@CR17]--[@CR26]\], seven were excluded for phenytoin concentrations not being assessed \[[@CR27]--[@CR33]\], five were excluded for both subjects not originating from the MENA region and phenytoin concentrations not being assessed \[[@CR34]--[@CR38]\], one was excluded for genetic polymorphisms not being assessed \[[@CR39]\], and two were excluded for being poster abstracts \[[@CR40], [@CR41]\]. Between the five included studies*, CYP2C9\*1, \*2,* and *\*3; CYP2C19\*1, \*2,* and *\*3;* and multidrug resistance protein 1 \[*MDR1*, also known as ATP-binding cassette sub-family B member 1 (ABCB1)\] C3435T polymorphisms were evaluated. The study population, phenytoin regimen, and genetic polymorphism(s) assessed varied between studies; summaries of each study are provided in Table [1](#Tab1){ref-type="table"}.Fig. 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart of included studies \[[@CR146]\]. *MENA* Middle East and North Africa, *PHT* phenytoin Table 1Summary of studies assessing the impact of genetic polymorphisms on phenytoin pharmacokinetics and/or clinical outcomesStudy, yearCountry/study populationPHT dosing regimenGenotype(s)/reported allelic frequencies percentagePharmacokinetic outcomesAynacioglu et al. \[[@CR42]\]Turkey\
 Outpatients (*n* = 280); healthy volunteers (*n* = 218)\
  PHT PK analysis in healthy volunteer subgroup (*n* = 101)300 mg PO × 1\
 Sample collected 12-h post-dose*CYP2C9*\
 Study population\
  \*1 = 79.4\
  \*2 = 10.6\
  \*3 = 10\
 Population included in PHT PK analysis:\
  \*1 = 81.7\
  \*2 = 9.4\
  \*3 = 8.9GenotypeSerum PHT, mean mg/L (95% CI)CYP2C9\*1/\*1\
CYP2C9\*1/\*2\
CYP2C9\*1/\*3\
CYP2C9\*2/\*2\
CYP2C9\*2/\*3\
CYP2C9\*3/\*34.16 (3.86--4.46)\
5.52 (4.66--6.39)\
5.65 (4.86--6.43)\
6.58 (1.64--11.51)\
Not observed\
5.92^a^Genotypep-HPPH/PHT ratio (95% CI)CYP2C9\*1/\*1\
CYP2C9\*1/\*2\
CYP2C9\*1/\*3\
CYP2C9\*2/\*2\
CYP2C9\*2/\*3\
CYP2C9\*3/\*30.43 (0.39--0.47)\
0.26 (0.21--0.31)\
0.21 (0.18--0.24)\
0.14 (0.13--0.14)\
Not observed\
0.02^a^Kerb et al. \[[@CR43]\]Turkey\
 Healthy volunteers (*n* = 96)300 mg PO × 1\
 Sample collected 12-h post-dose*CYP2C9*\
 \*1 = 81.3\
 \*2 = 10.1\
 \*3 = 8.8\
*CYP2C19*\
 \*1 = 88.3\
 \*2 = 11.7\
*MDR1 (ABCB1) C3435T*\
 C = 52.6\
 T = 47.4GenotypeSerum PHT, mean mg/L ± SDCYP2C9\*1/\*1\
CYP2C9\*1/\*2\
CYP2C9\*1/\*3\
CYP2C9\*2/\*2\
CYP2C9\*2/\*3\
CYP2C9\*3/\*3\
CYP2C19\*1/\*1\
CYP2C19\*1/\*2\
CYP2C91\*2/\*2\
MDR1 CC\
MDR1 CT\
MDR1 TT4.20 ± 1.25\
5.52 ± 1.43\
5.54 ± 1.47\
6.58 ± 1.99\
Not observed\
5.92^a^\
4.73 ± 1.47\
4.49 ± 1.68\
4.40 ± 1.41\
4.27 ± 1.74\
4.85 ± 1.33\
4.87 ± 1.36Multiple linear regression indicates the number of polymorphic *CYP2C9* alleles and *MDR1\*T* alleles account for 14.1 and 1.3% of the variability in phenytoin serum concentrations, respectively (*r* ^2^ = 0.154, *p* = 0.0002)Ozkaynakci et al. \[[@CR44]\]Turkey\
 Epilepsy clinic outpatients taking PHT mono- or polytherapy (*n* = 101)\
  Seizure etiology: epilepsy, brain tumor, glioma, head trauma, or AVM\
  Polytherapy, mostly CBZ, LTG, or VPAMean dose  4.1 mg/kg/day PO\
Mean duration\
 96.6 weeks (≥7 days)\
*C* ~tr~ collected pre-dose*CYP2C9*\
 \*1 = 89.2\
 \*2 = 7.4\
 \*3 = 3.4\
*CYP2C19*\
 \*1 = 70.1\
 \*2 = 19.6\
 \*3 = 10.3Genotype group (CYP2C9, 2C19)Serum PHT *C* ~tr~, mean mg/L (SEM)\*1/\*1, \*1/\*1\
\*1/\*1, \*1/\*2\
\*1/\*1, \*1/\*3\
\*1/\*1, \*2/\*2\
\*1/\*1, \*2/\*3\
\*1/\*2, \*1/\*1\
\*1/\*2, \*1/\*2\
\*1/\*2, \*1/\*3\
\*1/\*3, \*1/\*1\
\*1/\*3, \*1/\*3\
\*1/\*3, \*2/\*3^\*^7.43 (0.73)^†^\
9.16 (1.46)^\*\*\*^\
7.51 (2.56)^\*\*\*^\
9.80 (4.52)^\*\*^\
10.35 (2.29)^\*\*\*^\
8.90 (1.30)^†^\
14.80 (2.90)\
16.20^\*^\
10.47 (4.68)\
10 (1.20)\
27.90 (1.85)^\*^Reference genotype group for all comparisons: ^\*\*^ *p* \< 0.05, ^\*\*\*^ *p* \< 0.005, ^†^ *p* \< 0.001Alhazzani et al. \[[@CR45]\]Saudi Arabia\
 Epileptic patients taking PHT monotherapy: drug responsive (*n* = 25), drug resistant (*n* = 25)300 mg PO daily ≥1 month\
 Multiple samples collected over 12 h following dose*MDR1 (ABCB1) C3435T*\
 Drug responsive\
  C = 88\
  T = 12\
Drug resistant\
  C = 70\
  T = 30PK parameters^b^GenotypeCCCTTT*C* ~max~ (mg/mL)\
*T* ~max~ (h)\
AUC~0--12h~ (mg h/mL)\
*t*½ (h)\
Cl (L/h)20.4 (0.29)\
6 (0.12)\
302 (0.45)\
19.2 (0.36)\
0.8 (0.11)28 (0.10)\
6 (0.08)\
545 (0.71)\
30.2 (0.12)\
0.5 (0.04)32 (0.16)\
6 (0.08)\
631 (0.48)\
33.3 (0.4)\
0.42 (0.21)Ebid et al. \[[@CR46]\]Egypt\
 Epilepsy clinic outpatients taking PHT for partial (*n* = 43) or generalized tonic-clonic (*n* = 57) seizures; healthy volunteers from blood bank unit (*n* = 50)\
  PHT phenotyping in epilepsy patients (*n* = 100)Baseline dose\
 100 mg PO BID ≥1 year\
Dose adjustment at 3 months: if drug resistant and *C* ~tr~ \<10 mg/L: 150 mg PO TID\
 If drug resistant and *C* ~tr~ 10--14 mg/L: 100 mg PO TID\
 If drug responsive and/or *C* ~tr~ ≥15 mg/L: stop PHT and end follow-up\
 *C* ~tr~ collected pre-dose*MDR1 (ABCB1) C3435T*\
 Drug responsive\
  C = 36.5\
  T = 63.5\
 Drug resistant\
  C = 74.6\
  T = 25.4\
 Healthy volunteers\
  C = 48\
  T = 523-month evaluation (*n* = 100)Responsive, *n* = 18 (%)Resistant, *n* = 82 (%)Serum PHT *C* ~tr~, mg/L\
 \<10\
 10 to \<15\
 ≥1550\
44.4\
6.779.3\
17.1\
3.7Genotype\
 CC\
 CT\
 TT0\
44.4\
55.648.8\
40.2\
116-month evaluation (*n* = 79)Responsive, *n* = 19 (%)Resistant, *n* = 60 (%)Serum PHT *C* ~tr~, mg/L\
 \<10\
 10 to \<15\
 ≥1510.5\
31.6\
57.915\
68.3\
16.7Genotype\
 CC\
 CT\
 TT26.3\
47.4\
26.358.3\
36.7\
5*AUC* ~*0--12h*~ area under the concentration--time curve from 0 to 12 h post-dose, *AVM* arteriovenous malformation, *BID* twice daily, *CBZ* carbamazepine, *CI* confidence interval, *Cl* clearance, *C* ~*max*~ maximum plasma concentration, *C* ~*tr*~ trough concentration, *CYP* cytochrome P450, *LTG* lamotrigine, *PHT* phenytoin, *p-HPPH* 5-(*p*-hydroxyphenyl)-5-phenylhydantoin metabolite, *PK* pharmacokinetic, *PO* orally by mouth, *SD* standard deviation, *SEM* standard error of the mean, *t½* half-life, *TID* three times daily, *T* ~*max*~ time to *C* ~max~, *VPA* valproic acid^a^From one individual, cannot calculate 95% CI, SD, or SEM^b^Mean (SEM) reported

Upon assessment, each of the five studies was rated to be of poor quality. The ratings of each study against the 14 quality assessment tool criteria are summarized in Table [2](#Tab2){ref-type="table"}. Factors contributing to poor quality ratings included: unclear descriptions of study subject selection, introducing potential for selection bias; insufficient reporting of study subjects' baseline characteristics; relatively small sample sizes, limiting the power to assess the impact of polymorphic genotypes with low frequencies; and absence of adjustments for potential confounders that could affect phenytoin pharmacokinetics (e.g., antiepileptic polytherapy, concomitant medications, comorbid medical conditions, or serum albumin levels) or clinical outcomes (e.g., seizure control at baseline, seizure etiology, or type of seizure).Table 2Summary of methodological quality ratings of included studies^a^CriteriaAynacioglu et al. \[[@CR42]\]Kerb et al. \[[@CR43]\]Ozkaynakci et al. \[[@CR44]\]Alhazzani et al. \[[@CR45]\]Ebid et al. \[[@CR46]\]1. Research question or objective clearly statedYesNoYesYesYes2. Study population clearly specified and definedNoNoNoNoNo3. At least 50% of eligible persons participateNRNRNRNRNR4a. All subjects selected from same or similar population and same time periodCDCDCDCDCD4b. Inclusion and exclusion criteria pre-specified and uniformly appliedNRNRYesYesYes5. Sample size justification, power description, or variance and effect estimate providedNoNoNoNoNo6. Exposure^b^ of interest measured prior to outcome(s) being measuredNANANANANA7. Timeframe sufficient to see association between exposure^b^ and outcome if it existedYesYesYesYesYes8. Study examined different levels of exposure^b^ as related to outcomeNANANANANA9. Exposure^b^ measures clearly defined, valid, reliable, and implemented consistentlyYesCDYesCDYes10. Exposure^b^ assessed more than once over timeNANANANANA11. Outcome measures clearly defined, valid, reliable, and implemented consistentlyYesCDCDCDYes12. Outcome assessors blinded to participant exposure statusNANANANANA13. Loss to follow-up after baseline was 20% or lessNANANANAYes14. Key potential confounding variables measured and adjusted for statisticallyNoNoNoNoNo*CD* cannot determine, *NA* not applicable, *NR* not reported^a^Studies were rated against the 14 criteria of the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, from the National Institutes of Health, National Heart, Lung, and Blood Institute \[[@CR16]\]^b^Exposure was defined as study participants' allelic make-up for the polymorphism of interest

A total of 82 studies were conducted within the MENA region and investigated the prevalence of *CYP2C9*, *CYP2C19*, and/or *MDR1* variant alleles \[[@CR27], [@CR29], [@CR42]--[@CR121]\]. These studies were included in the secondary part of the review. Specific single nucleotide polymorphisms reviewed were*: CYP2C9\*1*, *\*2*, and *\*3*; *CYP2C19\*1*, *\*2*, and *\*3*; and *MDR1 (ABCB1)* C3435T. The study populations and computed genotypic and allelic frequencies for *CYP2C9*, *CYP2C19*, and *MDR1* are summarized in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, and [5](#Tab5){ref-type="table"}, respectively.Table 3Genotypic and allelic frequencies of *CYP2C9* in the Middle East and North Africa regionReferencesCountryStudy populationSample sizeGenotypic frequencies (%)Allelic frequencies (%)\*1/\*1\*1/\*2\*1/\*3\*2/\*2\*2/\*3\*3/\*3\*1\*2\*3\[[@CR47]\]EgyptHealthy volunteers24766.419.011.72.400.481.811.96.3\[[@CR48]\]EgyptHealthy volunteers (*n* = 154), patients taking maintenance warfarin (*n* = 46)20081.54.58.54.50.50.588.07.05.0\[[@CR49]\]EgyptWarfarin-resistant patients4160.919.519.500080.49.89.8Warfarin-responsive patients3073.320.06.700086.710.03.3\[[@CR50]\]EgyptPatients taking maintenance warfarin6376.27.96.33.206.383.47.19.5\[[@CR51]\]EgyptPatients taking maintenance warfarin8483.3NA11.9NANA4.889.3NA10.7\[[@CR52]\]Egypt^a^Patients taking maintenance warfarin20762.617.411.81.04.11.074.211.18.5\[[@CR53]\]IranHealthy volunteers20082.010.507.50087.212.80\[[@CR54]\]IranHealthy volunteers5082.012.06.000091.06.03.0Patients taking maintenance valproic acid6880.911.84.41.51.5089.08.12.9\[[@CR55]\]IranWarfarin-sensitive patients2119.066.714.300052.447.6NAPatients with normal warfarin response3775.721.62.700086.513.5NA\[[@CR56]\]IranPatients taking maintenance warfarin10039.041.09.02.09.0064.027.09.0\[[@CR57]\]JordanHealthy volunteers26362.721.712.21.91.5079.713.56.8\[[@CR58]\]KuwaitPatients taking maintenance warfarin10869.421.36.502.8083.412.04.6\[[@CR59]\]LibyaHealthy volunteers16165.814.913.71.92.51.280.110.69.3\[[@CR60]\]LibyaPatients taking maintenance VKA23160.622.510.02.23.90.976.815.47.8\[[@CR61]\]MoroccoLow-dose acenocoumarol2055.025.05.010.005.070.022.57.5Medium-dose acenocoumarol5872.419.06.91.70085.411.23.4High-dose acenocoumarol3694.42.802.80095.84.20\[[@CR62]\]Oman^a^Patients taking maintenance warfarin21273.611.38.5NA2.40.984.26.86.4\[[@CR63]\]OmanPatients taking maintenance warfarin18980.412.75.81.10089.67.52.9\[[@CR64]\]Saudi ArabiaHealthy volunteers13168.726.74.600084.313.42.3\[[@CR65]\]Saudi ArabiaHealthy volunteers19264.117.213.02.12.11.679.211.79.1\[[@CR66]\]Sudan^a^Patients taking maintenance warfarin20371.98.9000084.04.90\[[@CR67]\]Tunisia^a^Healthy volunteers25861.619.413.22.73.1077.914.08.1\[[@CR43]\]TurkeyHealthy volunteers9666.713.515.63.101.081.29.98.9\[[@CR68]\]TurkeyHealthy volunteers6464.014.115.63.103.178.910.210.9\[[@CR69]\]TurkeyHealthy volunteers8568.211.814.13.51.21.281.210.08.8\[[@CR42]\]TurkeyHealthy volunteers (*n* = 218), outpatients with variable diagnoses (*n* = 280)49961.718.017.21.01.10.879.410.610.0\[[@CR44]\]TurkeyOutpatients of epilepsy clinic10278.414.76.900089.27.43.4\[[@CR70]\]Turkey^a^Patients taking maintenance warfarin20560.018.013.71.53.91.076.812.79.8\[[@CR71]\]TurkeyPatients taking maintenance warfarin10050.021.024.005.0072.513.014.5\[[@CR72]\]TurkeyPatients taking maintenance anticoagulant29256.523.08.63.07.21.772.218.29.6*CYP* cytochrome P450, *NA* not assessed, *VKA* vitamin-K antagonist, *VPA* valproic acid^a^Additional CYP2C9 alleles assessed; therefore, percentages do not add to 100% Table 4Genotypic and allelic frequencies of *CYP2C19* in the Middle East and North Africa regionReferencesCountryStudy populationSample sizeGenotypic frequencies (%)Allelic frequencies (%)\*1/\*1\*1/\*2\*1/\*3\*2/\*2\*2/\*3\*3/\*3\*1\*2\*3\[[@CR67]\]Bahrain^a^Healthy volunteers7533.333.3NA8.0NANA53.326.0NA\[[@CR47]\]EgyptHealthy volunteers24778.520.20.40.80088.910.90.2\[[@CR73]\]EgyptMale agricultural workers12093.35.8NA0.8NANA96.23.8NA\[[@CR74]\]Gaza StripChildren with hematological malignancy5280.815.41.91.90089.49.61.0Healthy volunteers20086.56.51.530.52.090.56.53.0\[[@CR53]\]IranHealthy volunteers20075.022.003.00086.014.00\[[@CR75]\]Iran^a^Healthy volunteers18041.718.3NA2.2NANA65.313.10\[[@CR27]\]IranHealthy volunteers of Baluch descent14078.620.00.7000.788.910.01.1\[[@CR76]\]IranPatients with erosive reflux esophagitis8270.724.33.71.30084.813.41.8\[[@CR56]\]IranPatients taking maintenance warfarin9976.821.20.100.1087.911.11.0\[[@CR77]\]IranPatients taking clopidogrel for elective PCI112NR89.010.10.9\[[@CR78]\]IranPatients with PCI for CAD4372.123.3NA4.7NANA83.716.3NA\[[@CR79]\]IranPatients with in-stent restenosis while taking appropriate DAPT for PCI5086.014.0NA0NANA93.07.0NAPatients without in-stent restenosis while taking DAPT for PCI5092.08.0NA0NANA96.04.0NA\[[@CR80]\]IsraelHealthy volunteers14070.725.01.42.90083.915.40.7\[[@CR81]\]IsraelVolunteers of Yemenite descent3677.819.402.80087.512.50Volunteers of Bedouin descent5076.020.02.02.00087.012.01.0\[[@CR57]\]JordanHealthy volunteers15878.518.403.20087.712.30\[[@CR82]\]JordanHealthy male volunteers7874.419.206.40084.016.00\[[@CR67]\]Kuwait^a^Healthy volunteers10041.035.0NA3.0NANA61.522.0NA\[[@CR83]\]LebanonHealthy volunteers16175.820.50.63.10086.313.40.3\[[@CR84]\]Saudi Arabia^a^Healthy volunteers20140.314.4NA0.005NANA62.911.2NA\[[@CR85]\]Saudi ArabiaHealthy military recruits97NR87.013.00\[[@CR86]\]Saudi ArabiaPatients taking clopidogrel for ACS9067.03.0032.00067.832.20\[[@CR67]\]Tunisia^a^Healthy volunteers25847.312.8NA0.3NANA69.88.90\[[@CR43]\]TurkeyHealthy volunteers9478.116.7NA3.1NANA88.311.70\[[@CR87]\]TurkeyHealthy volunteers40476.022.30.71.00087.512.10.4\[[@CR44]\]TurkeyOutpatients of epilepsy clinic10255.917.610.85.99.8070.119.610.3\[[@CR88]\]Turkey^a^Children, 2--18 years old24444.312.301.20065.610.00\[[@CR89]\]TurkeyPatients taking clopidogrel for ICVD5170.625.503.90083.316.70*ACS* acute coronary syndrome, *CAD* coronary artery disease, *CYP* cytochrome P450, *DAPT* dual anti-platelet therapy, *ICVD* ischemic cerebrovascular disease, *MACE* major adverse cardiac event, *NA* not assessed, *NR* not reported, *PCI* percutaneous coronary intervention^a^Additional CYP2C19 alleles assessed; therefore, percentages do not add to 100% Table 5Genotypic and allelic frequencies of *MDR1* (*ABCB1*) C3435T in the Middle East and North Africa regionReferencesCountryStudy populationSample sizeGenotypic frequencies (%)Allelic frequencies (%)CCCTTTCT\[[@CR46]\]EgyptHealthy volunteers5024.048.028.048.052.0Patients with drug-responsive epilepsy3713.546.040.536.563.5Patients with drug-resistant epilepsy6355.638.16.374.625.4\[[@CR90]\]EgyptPatients taking clopidogrel for ACS or PCI who experienced MACE8439.347.613.163.136.9Patients taking clopidogrel for ACS or PCI who did not experience MACE10637.744.317.959.940.1\[[@CR91]\]EgyptPatients taking maintenance warfarin8429.854.815.457.142.9\[[@CR92]\]EgyptPatients with hypercholesterolemia5038.040.022.058.042.0\[[@CR93]\]EgyptPatients taking imatinib for newly diagnosed Philadelphia chromosome-positive CML10044.047.09.067.532.5\[[@CR94]\]EgyptHealthy child volunteers3528.648.622.947.152.9Children with immune thrombocytopenia488.362.527.167.632.4\[[@CR95]\]IranPatients admitted for primary care93331.664.53.949.150.9\[[@CR96]\]IranHealthy volunteers20023.545.031.546.054.0Patients with drug-responsive epilepsy20016.040.044.036.064.0Patients with drug-resistant epilepsy13225.741.732.646.653.4\[[@CR97]\]IranIranian Azeri Turkish volunteers9219.653.327.246.253.8Iranian Azeri Turkish patients with Behçet's disease6918.846.434.842.058.0\[[@CR98]\]IranHealthy female volunteers20070.525.04.583.017.0Female patients with breast cancer10075.016.09.083.017.0\[[@CR99]\]IranHealthy female volunteers5418.555.625.947.053.0Female patients with breast cancer5020.054.026.046.353.7\[[@CR100]\]IranHealthy female volunteers7715.658.426.044.855.2Female patients with breast cancer10615.153.731.142.058.0\[[@CR101]\]JordanHealthy volunteers10017.050.033.042.058.0\[[@CR102]\]JordanPatients of ear, nose, and throat clinic25116.348.235.440.459.6\[[@CR103]\]JordanPatients receiving methotrexate for RA15937.745.317.060.439.6\[[@CR104]\]JordanHealthy female volunteers15026.743.330.048.351.7Female patients with breast cancer15045.341.313.366.034.0\[[@CR105]\]LebanonChildren with ALL12727.644.128.349.650.4\[[@CR106]\]MoroccoHealthy volunteers10039.051.010.064.535.5\[[@CR107]\]Saudi ArabiaHealthy volunteers17935.245.219.657.842.2\[[@CR108]\]Saudi ArabiaHealthy female volunteers10093.05.02.095.54.5Female patients with breast cancer10073.011.016.078.521.5\[[@CR45]\]Saudi ArabiaPatients with PHT-responsive epilepsy2580.020.088.012.0Patients with PHT-resistant epilepsy2552.048.070.030.0\[[@CR43]\]TurkeyHealthy volunteers9629.246.924.052.647.4\[[@CR109]\]TurkeyHealthy volunteers10727.141.131.847.752.3\[[@CR110]\]TurkeyHealthy volunteers17428.246.025.951.148.9Patients with CBZ-responsive epilepsy5330.254.715.157.542.5Patients with CBZ-resistant epilepsy4429.559.111.459.140.9\[[@CR29]\]TurkeyChildren with drug-responsive epilepsy8326.545.827.749.450.6Children with drug-resistant epilepsy6924.643.531.946.453.6\[[@CR111]\]TurkeyPatients receiving fentanyl for spinal anesthesia8328.954.216.956.044.0\[[@CR112]\]TurkeyPatients with normal CAG8527.141.231.847.652.4Patients with CAD found on CAG11327.448.723.951.848.2\[[@CR113]\]TurkeyHealthy male volunteers10226.549.024.551.049.0Male individuals with primary infertility19227.657.315.156.343.7\[[@CR114]\]TurkeyHealthy volunteers13025.444.630.047.752.3Patients with familial Mediterranean fever14216.959.923.246.853.2\[[@CR115]\]TurkeyHealthy volunteers25027.242.430.448.451.6Patients with familial Mediterranean fever30920.455.324.348.151.9\[[@CR116]\]TurkeyPatients with familial Mediterranean fever413.754.243.429.270.8\[[@CR117]\]TurkeyRenal transplant recipients taking tacrolimus9230.447.821.754.345.7\[[@CR118]\]TurkeyRenal transplant recipients taking cyclosporine who did not develop gingival hyperplasia11427.244.728.149.650.4Renal transplant recipients taking cyclosporine who developed gingival hyperplasia4032.537.530.051.348.7\[[@CR119]\]TurkeyPatients taking clozapine who did not develop agranulocytosis9129.753.816.556.643.4Patients taking clozapine who developed agranulocytosis1020.060.020.050.050.0\[[@CR120]\]TurkeyPatients with non-small-cell lung cancer7924.162.013.955.144.9\[[@CR121]\]TurkeyHealthy volunteers150NR52.347.7Patients with colorectal cancer103NR61.238.8*ACS* acute coronary syndrome, *ALL* acute lymphoblastic leukemia, *AML* acute myeloid leukemia, *CAD* coronary artery disease, *CAG* coronary angiography, *CBZ* carbamazepine, *CML* chronic myeloid leukemia, *MACE* major adverse cardiac event, *NA* not assessed, *NR* not reported, *PCI* percutaneous coronary intervention, *PHT* phenytoin, *RA* rheumatoid arthritis

CYP2C9 {#Sec10}
------

CYP2C9 accounts for 70--90% of phenytoin metabolism \[[@CR122]\], with (*S*)-5-(*p*-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) being the major resultant metabolite \[[@CR5], [@CR7]\]. Although up to 60 different CYP2C9 haplotypes have been identified, *CYP2C9\*2* and *\*3* are the two most common allelic variants \[[@CR123], [@CR124]\]. Both variants exhibit reduced functional activity, with losses of 29 and 94% enzymatic activity reported for *CYP2C9\*2* and *\*3*, respectively, when compared with the wild-type genotype \[[@CR125], [@CR126]\]. Three of the included studies investigated *CYP2C9* genotypes \[[@CR42]--[@CR44]\].

Aynacioglu et al. \[[@CR42]\] genotyped all outpatients and healthy volunteers for CYP2C9, and phenotyped phenytoin through assessment of serum phenytoin and p-HPPH concentrations in a subset of 101 of the Turkish healthy volunteers. Twelve hours following a single dose of phenytoin, serum phenytoin concentrations differed significantly across groups with 0, 1, and 2 loss of function mutations (*p* \< 0.001). Study results indicated serum phenytoin concentration in the *CYP2C9\*1/\*1* wild-type genotype group was significantly lower when compared with *CYP2C9\*1/\*2*, *CYP2C9\*1/\*3*, and *CYP2C9\*2/\*2* genotype groups, with the difference in means being −1.36 mg/L (*p* = 0.009), −1.49 mg/L (*p* = 0.001), and −2.42 mg/L (*p* = 0.02), respectively. Accordingly, results also indicated the ratio of serum p-HPPH-to-phenytoin concentration of the *CYP2C9\*1/\*1* wild-type genotype group was significantly higher than that of *CYP2C9\*1/\*2*, *CYP2C9\*1/\*3*, and *CYP2C9\*2/\*2* genotype groups, with the difference in means being 0.17 (*p* = 0.002), 0.22 (*p* \< 0.0001), and 0.29 (*p* = 0.006), respectively. Differences between wild-type and *CYP2C9\*3/\*3* genotypes were not compared statistically, as the latter was present in only one individual.

It was identified that data from the 96 healthy Turkish volunteers in the study conducted by Kerb et al. \[[@CR43]\] were derived from the 101 volunteers of the Aynacioglu et al. study \[[@CR42]\]. Thus, the results regarding influence of *CYP2C9* genotype on measured phenytoin concentrations and the p-HPPH-to-phenytoin ratio are reflected in the aforementioned results \[[@CR42], [@CR43]\]. Using these data in a multiple linear regression analysis, Kerb et al. determined that the number of polymorphic *CYP2C9* alleles accounted for 14.1% of variability in phenytoin serum concentrations \[[@CR43]\]. The final regression equation, which also included the number of *MDR1* C3435T alleles, had an *r* ^2^ = 0.154 (*p* = 0.0002).

Ozkaynakci et al. \[[@CR44]\] reported data for 11 different combinations of *CYP2C9* and *CYP2C19* genotypes; therefore, the independent impact of the CYP2C9 genotype on serum phenytoin concentrations was difficult to discern. When compared with the *CYP2C9* and *CYP2C19* wild-type genotype group, *CYP2C9\*1/\*3*, *CYP2C19\*2/\*3* was the only genotype group with a serum phenytoin trough that was significantly different, with a mean concentration that was 20.47 mg/L higher than the wild-type genotype group (*p* \< 0.001). The mean serum phenytoin trough of the *CYP2C9\*1/\*3, CYP2C19\*2/\*3* genotype group was also significantly higher than several other genotype groups (Table [1](#Tab1){ref-type="table"}). Clinical outcomes associated with *CYP2C9* polymorphisms were not reported and therefore could not be assessed.

CYP2C19 {#Sec11}
-------

CYP2C19 accounts for 10--30% of phenytoin metabolism, with greater metabolic contributions as CYP2C9 becomes saturated \[[@CR122], [@CR127]\]. CYP2C19 primarily forms the (*R*)-p-HPPH metabolite \[[@CR5], [@CR7]\]. Up to 35 different CYP2C19 haplotypes have been identified, of which *CYP2C19\*2* and *\*3* are the two most common null alleles; presence of two null alleles results in a non-functional CYP2C19 enzyme \[[@CR124], [@CR125]\]. A third haplotype, *CYP2C19\*17*, results in increased expression and activity of the enzyme \[[@CR125]\]; however, this haplotype was not assessed in the included studies. Two of the included studies investigated *CYP2C19* genotypes \[[@CR43], [@CR44]\].

In the study conducted by Kerb et al. \[[@CR43]\], the *CYP2C19* genotype did not significantly affect serum phenytoin concentration (*p* = 0.52) or p-HPPH-to-phenytoin ratio (*p* value not reported). As with CYP2C9, as a result of Ozkaynakci et al. \[[@CR44]\] reporting the data for 11 different *CYP2C9* and *CYP2C19* genotype groups, it is difficult to distinguish the independent impact of *CYP2C19* genotype on serum phenytoin concentrations; therefore, no inferences can be made. As with CYP2C9, clinical outcomes were not reported and therefore could not be assessed.

MDR1 (ABCB1) C3435T {#Sec12}
-------------------

The *MDR1* (*ABCB1*) gene encodes for human P-glycoprotein, an efflux transporter of which phenytoin is a substrate \[[@CR128], [@CR129]\]. The *MDR1* C3435T polymorphism is a silent mutation that decreases transporter expression and alters substrate specificity \[[@CR130], [@CR131]\]; therefore, it has the potential to affect substrate absorption and tissue distribution. The resultant impact of this polymorphism on pharmacokinetic and pharmacodynamic outcomes of phenytoin therapy is unclear \[[@CR7], [@CR130], [@CR132]\]. Three of the included studies investigated the *MDR1* C3435T polymorphism \[[@CR43], [@CR45], [@CR46]\].

Kerb et al. \[[@CR43]\] identified that the *MDR1* C3435T genotype did not significantly impact serum phenytoin concentration overall (*p* = 0.064), and the number of *MDR1 T* alleles accounted for only 1.3% of the variability in serum phenytoin concentrations in their multiple regression analysis. As discussed previously, the final regression equation had an *r* ^2^ = 0.154 (*p* = 0.0002). When serum phenytoin concentrations were divided into quartiles (25th percentile: \<3.79 mg/L, interquartile range: 3.79--5.79 mg/L, 75th percentile: \>5.79 mg/L), the frequency distribution of MDR1 genotype indicated that the *MDR1 CC* genotype was more frequent in the 25th percentile group (*p* ≤ 0.001, *χ* ^2^ test). Moreover, while the presence of the *MDR1 TT* genotype reportedly had significant influence on p-HPPH-to-phenytoin ratio (*p* \< 0.026), absolute values were not provided and there was considerable overlap in the depicted frequency distribution; therefore, clinical significance of this association cannot be inferred.

Alhazzani et al. \[[@CR45]\] identified significant differences between the *CC*, *CT*, and *TT* genotypes (classified as extensive, intermediate, or poor metabolizers, respectively) for the pharmacokinetic parameters of maximum plasma concentration (*p* \< 0.01), area under the plasma concentration--time curve from 0 to 12 h post-dose (*p* \< 0.01), half-life (*p* \< 0.01), and clearance (*p* \< 0.01) using one-way analysis of variance. However, post-hoc analyses were not performed to identify which genotypes differed significantly for these parameters. There was no difference between genotype groups for the parameter of time to maximum plasma concentration (*p* \> 0.05). The reported values for each genotype are presented in Table [1](#Tab1){ref-type="table"}. Moreover, a significant association between the *MDR1* C3435T genotype and phenytoin response was reported. Non-responders (i.e., phenytoin-resistant patients) had a higher frequency of the *T* allele (*χ* ^2^ = 9.76, *p* = 0.0017) and, accordingly, the *CT* or *TT* genotypes (*χ* ^2^ = 4.37, *p* = 0.036). The odds ratio (OR) calculated from the identified frequencies was significant for the allelic frequency \[OR 3.14; 95% confidence interval (CI) 1.42--7.05\], but not for the genotypic (OR 3.69; 95% CI 0.90--5.81).

Ebid et al. \[[@CR46]\] did not identify a significant association between drug resistance or responsiveness and phenytoin concentrations overall, but reported associations between the *MDR1 CC* genotype and the likelihood of drug-resistant patients having serum phenytoin trough concentrations below or in the lower half of therapeutic range at the 3- and 6-month evaluations. Whether the *MDR1* C3435T genotype influences the efficacy and toxicity of phenytoin in epilepsy management was also explored. Overall, patients who were drug resistant (i.e., had seizure recurrence in the preceding 3 months) were more likely to have the *MDR1 CC* genotype than the *MDR1 TT* genotype when compared with patients responsive to therapy (55.5 vs. 13.5%, *χ* ^2^ = 24.99; *p* \< 0.0001). Moreover, as would be expected, within the drug-resistant group, seizures occurred at higher frequency in patients with serum phenytoin trough \<10 mg/L, with average seizure frequencies of 4.4 and 3.7 at 3 and 6 months, respectively (*p* \< 0.0001).

Genotypic and Allelic Frequencies Within the MENA Region {#Sec13}
--------------------------------------------------------

Variant MAF of *CYP2C9*, *CYP2C19*, and *MDR1 (ABCB1)* C3435T have been investigated in a variety of settings and study populations across the MENA region. Studies from 11 different countries were identified for both *CYP2C9* and *CYP2C19*, and seven countries for *MDR1 (ABCB1)* C3435T; study populations and computed genotypic and allelic frequencies for each polymorphism are summarized in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, and [5](#Tab5){ref-type="table"}, respectively. Overall, there was appreciable variability in MAF both between and within countries of the MENA region for each of *CYP2C9*, *CYP2C19*, and *MDR1 (ABCB1)* C3435T. For example, in studies assessing subjects of Turkish origin, the reported *CYP2C19\*3* MAF ranged from 0 to 10.3% \[[@CR43], [@CR44], [@CR87]--[@CR89]\].

Discussion {#Sec14}
==========

The purpose of this systematic review was to evaluate the role of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes specifically in populations originating from the MENA region, and to characterize assessed polymorphism variant MAF within the region. Recognizing and understanding factors that contribute to interpatient variability in pharmacokinetics, pharmacodynamics, and associated clinical outcomes is essential to providing patient-individualized pharmacotherapy and disease management. In the management of epilepsy and seizure disorders, the significant role of genetic polymorphisms as one such factor has received increasing recognition, with phenytoin being an antiepileptic drug of particular interest, owing to its unique pharmacokinetic and pharmacodynamic profile \[[@CR5], [@CR6], [@CR17]--[@CR26], [@CR35], [@CR38]--[@CR46], [@CR127], [@CR133], [@CR134]\]

CYP2C9 {#Sec15}
------

Findings of the studies included in this review indicate that the reduced functional capacity of CYP2C9 enzymes with *CYP2C9\*2* and *CYP2C9\*3* variant alleles results in significantly higher serum phenytoin concentrations \[[@CR42]--[@CR44]\]. This difference was significant after only a single dose of phenytoin in healthy volunteers included in the studies by Aynacioglu et al. \[[@CR42]\] and Kerb et al. \[[@CR43]\]. Although the absolute difference between the wild-type genotype and those with one or two reduced function alleles was only in the range of 1.32--2.42 mg/L, owing to the reduced functional capacity of enzymes with variant alleles, it is reasonable to surmise that the absolute difference in phenytoin concentrations would likely be of clinical significance with repeat dosing \[[@CR5]\]. This notion is supported by an in-vitro study of *CYP2C9* polymorphisms, wherein *\*2* and *\*3* allelic variants decreased maximal velocity by 29 and 79%, respectively, and while the *\*2* variant did not affect the Michaelis constant, the *\*3* variant increased it fourfold \[[@CR126]\].

Ozkaynakci et al. \[[@CR44]\] reported a statistically significant difference between the wild-type and *CYP2C9\*1/\*3, CYP2C19\*2/\*3* genotype groups. However, five of the 11 reported genotype groups had frequencies of only 0.98--2.94%, which likely limited the power of the study to detect differences between the wild-type and other genotype groups. Moreover, patients were required to have been taking phenytoin for only 7 days. Therefore, it is possible that some patients were not yet at steady state when phenytoin trough concentrations were drawn, and that absolute differences in concentrations would be statistically and/or clinically significant over time \[[@CR5]\]. This is especially noteworthy in those with *CYP2C9\*2* or *\*3* alleles, in whom reduced functional capacity may significantly prolong the time necessary to achieve steady-state concentrations \[[@CR5], [@CR46]\]. As well, patients were not on a fixed dose of phenytoin; therefore, knowing the mean dose within each genotype group or having a serum concentration adjusted for mean dose in each genotype group would allow for assessment of this as a potential confounder. Although the impact of polytherapy was explored, the study was underpowered to appropriately assess this outcome. Thus, these results do not provide a clear demonstration of the impact of *CYP2C9\*2* and \**3* allelic variants on phenytoin pharmacokinetics.

The impact of *CYP2C9* variants have been more clearly demonstrated in studies conducted in non-MENA populations. In a cohort of Japanese pediatric patients, when controlling for *CYP2C19* polymorphisms, patients with the *CYP2C9\*1/\*3* genotype required phenytoin maintenance doses that were 37.3% lower than those with the wild-type genotype to achieve target concentrations of 15--20 mg/L \[[@CR10]\]. Similarly, in a sample of Dutch patients, those with at least one *CYP2C9\*2* or *\*3* allele required phenytoin maintenance doses that were 37% lower to achieve target concentrations of 10--20 mg/L \[[@CR24]\]. A study of patients originating from India indicated that those with the *CYP2C9\*1/\*3* genotype were more likely than the wild-type genotype to have serum phenytoin concentrations \>20 mg/L (OR 4.8; 95% CI 1.89--12.17; *p* 0.001), despite receiving comparable maintenance doses of phenytoin (5.4 vs. 5.1 mg/kg/day; *p* = 0.16) \[[@CR133]\]. In addition to the impact of *CYP2C9* polymorphisms on phenytoin pharmacokinetics in non-MENA populations, it also had an effect on phenytoin safety outcomes. A case-control study of Thai patients demonstrated that, when on comparable maintenance phenytoin doses, patients with the *CYP2C9\*1/\*3* genotype were more likely to develop phenytoin-induced severe cutaneous adverse reactions (i.e., Stevens--Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms) within 12 weeks of initiating therapy than those with the wild-type genotype (OR 14.52; 95% CI 1.18--∞; *p* 0.044) \[[@CR134]\]. This association is supported by findings of a meta-analysis conducted in Asian populations, wherein the *CYP2C9\*3* allele was associated with an increased risk of phenytoin-induced severe cutaneous reactions (OR 11.0; 95% CI 6.2--18.0; *p* \< 0.00001) \[[@CR17]\]. Furthermore, in a case-control study of Tamilian patients, when adjusting for phenytoin maintenance dose, patients with the *CYP2C9\*1/\*3* genotype were significantly more likely to experience phenytoin-induced neurological toxicity (e.g., ataxia, slurred speech, lethargy, nystagmus) when compared with wild-type genotype (adjusted OR 15.3; 95% CI 5.8--40.3; *p* 0.0001) \[[@CR22]\].

Ultimately, the significant impact of *CYP2C9\*2* and *\*3* allelic variants on phenytoin pharmacokinetics and risk of adverse effects when standard doses are administered has led to development of genotype-specific recommendations. It is suggested that initial doses of phenytoin be reduced by 25% in patients with one variant allele (i.e., *CYP2C9\*1/\*2* or *\*1/\*3*) and by 50% in patients with two variant alleles (i.e., *CYP2C9\*2/\*2, \*2/\*3* or *\*3/\*3*) \[[@CR8]\].

CYP2C19 {#Sec16}
-------

Results of this review suggest that *CYP1C19\*2* and *\*3* allelic variants, on their own, did not significantly impact the pharmacokinetics of phenytoin. In the single-dose study by Kerb et al. \[[@CR43]\], using the same rationale as discussed with CYP2C9, although *CYP2C19\*1/\*2* and *\*2/\*2* genotypes were not associated with significantly different phenytoin serum concentrations, owing to the non-functional nature of *\*2* alleles, it is possible that statistically and clinically differences would arise after repeat dosing \[[@CR5]\].

For results regarding CYP2C19 reported by Ozkaynakci et al. \[[@CR44]\], previously discussed limitations affecting interpretation of results regarding CYP2C9 also apply. Both studies included in this review were likely underpowered to assess the impact of *CYP2C19* polymorphisms specifically. Moreover, because CYP2C19 accounts for only 10--30% of phenytoin metabolism \[[@CR122], [@CR127]\], decreased or loss of functional capacity may be less likely to significantly affect phenytoin serum concentrations when compared with *CYP2C9* allelic variants with reduced function.

Evidence from studies conducted in non-MENA populations suggest that CYP2C19 allelic variants may significantly impact pharmacokinetics of phenytoin. In the previously described Japanese cohort, those with *CYP2C9* wild-type genotype and one variant *CYP2C19* allele (i.e., *CYP2C19\*1/\*2* or *\*1/\*3*) required phenytoin doses 13.1% lower than patients with wild-type genotypes of both *CYP2C9* and *CYP2C19* to achieve target concentrations (*p* \< 0.01), while those with two variant *CYP2C19* alleles (i.e., *CYP2C19\*2/\*2*, *\*2/\*3, or \*3/\*3)* required doses 28.1% lower (*p* \< 0.001) \[[@CR10]\]. Regarding clinical outcomes, in the study conducted in Tamilian patients, when adjusting for maintenance dose, patients with *CYP2C19\*2/\*2* genotype were significantly more likely to experience phenytoin-induced neurological toxicity when compared with wild-type genotype (adjusted OR 3.0; 95% CI 1.3--7.0; *p* 0.01) \[[@CR22]\]. Evidence from studies assessing both *CYP2C9* and *CYP2C19* genotypes suggest additive impact on phenytoin concentrations when variant genotypes of both enzymes are present \[[@CR20], [@CR22]\]. Although official guidelines have not been developed for dosage adjustments in patients with *CYP2C19* allelic variants, recommendations for both pediatric and adult patients have been suggested based on the combination of both *CYP2C9* and *CYP2C19* genotypes \[[@CR10], [@CR20]\].

MDR1 (ABCB1) C3435T {#Sec17}
-------------------

The reported impact of the *MDR1* C3435T genotype on phenytoin pharmacokinetics in this review was inconsistent, and results in all three studies \[[@CR43], [@CR45], [@CR46]\] may have been confounded because of aforementioned factors such as concomitant medications, comorbid conditions, and serum albumin levels, among other patient-specific factors.

Kerb et al. \[[@CR43]\] reported no significant association between *MDR1* genotype and serum phenytoin concentrations overall. Although post-hoc analysis identified a significant association between the *MDR1 CC* genotype and serum phenytoin concentrations in the 25th percentile, the association is likely of limited clinical significance because of the narrow concentration range defined by the three classes of low, medium, and high. Unlike CYP2C9 and CYP2C19, transporters encoded by *MDR1* are not involved in phenytoin metabolism; therefore, it is unclear whether repeat dosing over time would significantly impact the observed degree of difference in phenytoin serum concentrations between genotype groups. Moreover, although presence of *MDR1 T* alleles accounted for 1.3% of variability in phenytoin serum concentrations, the clinical relevance of this is questionable, especially considering the final regression equation could account for only 15.4% of observed variability \[[@CR43]\].

In contrast, results reported by Alhazzani et al. \[[@CR45]\] indicate all pharmacokinetic parameters, with the exception of time to maximum plasma concentration, were significantly affected by the *MDR1* C3435T genotype. In the absence of post-hoc analyses of the one-way analysis of variance, which genotypes significantly differed for these parameters cannot be confirmed; however, the results trend toward the *MDR1 CC* genotype group being different. Of note, the classification of extensive, intermediate, and poor metabolizer to describe the *MDR1* C3435T genotype is misleading, as proteins encoded by *MDR1* are involved in substrate absorption and distribution, not metabolism \[[@CR129]--[@CR131]\]. The trend of increased maximum plasma concentration, area under the plasma concentration--time curve from 0 to 12 h post-dose, half-life, and clearance in subjects with one or more *T* alleles holds face validity, as this variant is associated with lower levels of transporter expression \[[@CR130]\], which, at the level of the intestine, would result in less phenytoin being effluxed from systemic circulation back into the intestinal lumen. The distributions of responders and non-responders across the extensive, intermediate, and poor metabolizer categories were not reported; therefore, associations between the *MDR1* C3435T genotype, phenytoin pharmacokinetics, and resultant clinical outcomes could not be assessed.

The clinical significance of the association between serum phenytoin level and *MDR1* C3435T genotype reported by Ebid et al. \[[@CR46]\] is unclear. Specifically, at the 3-month evaluation, there was no significant association between phenytoin responsiveness and serum concentration overall, while at the 6-month evaluation, a 'higher' concentration in the drug-responsive group was not defined and whether or not weight adjusting the doses mitigated reported differences was not explored.

Reported associations between the *MDR1* C3435T genotype and drug resistance reported in this review are conflicting \[[@CR45], [@CR46]\]. Historically, associations between drug-resistant epilepsy and overexpression of transporters encoded by *MDR1* have been reported \[[@CR135]--[@CR137]\]. Despite this, several limitations must be considered when interpreting the clinical outcomes reported by Ebid et al. \[[@CR46]\]. Foremost, distribution of seizure type within the drug-responsive and drug-resistant groups was not reported, nor adjusted for in the results. This is notable, as there is evidence to suggest phenytoin may aggravate generalized seizures \[[@CR3]\]. Additional potential confounders, such as baseline seizure control and concomitant antiepileptic drugs, were also not adjusted for. It is unclear if appropriate corrections were made for multiple statistical analyses; thus, it is possible that identified associations were the result of chance.

The association of *MDR1* C3435T genetic polymorphisms and drug-resistant epilepsy in general (as opposed to phenytoin specifically) was assessed within Iranian patients \[[@CR33]\]. The *MDR1 CC* wild-type genotype was significantly more frequent in drug-resistant patients, and associations were also made with adult age and female sex; however, the latter two associations may have resulted from performing multiple statistical analyses. The investigators attempted to address confounders such as baseline etiology and seizure type through univariate analyses; however, because baseline characteristics were so different between study groups, residual confounding likely remained \[[@CR33]\]. Two studies conducted in Turkish patients with seizure disorders did not find a significant association between the *MDR1* C3435T genotype and drug resistance \[[@CR29], [@CR110]\]. More recently, a meta-analysis of studies conducted in Asian, Caucasian (under which populations originating from the MENA region were classified), and Indian populations investigated the role of *MDR1* gene haplotypes in antiepileptic drug response \[[@CR132]\]. Initial results indicated that the presence of the T variant of *MDR1* C3435T may be associated with lower rates of drug resistance. Once corrected for multiple statistical analyses, there was no significant association overall, but a significant association remained in Caucasian patients (*T* vs. *C* allele, OR 0.83; 95% CI 0.71--0.96; *p* = 0.01) \[[@CR132]\]. One hypothesis regarding inconsistency in positive associations found between *MDR1* genotypes and responsiveness to antiepileptic drugs is that the gene falls within a significant block of high linkage disequilibrium \[[@CR138]\]. Therefore, it is possible that the associations identified are not the result of the *MDR1* polymorphism itself, but to an alternative gene within the linkage disequilibrium block \[[@CR138]\].

Genotypic and Allelic Frequencies Within the MENA Region {#Sec18}
--------------------------------------------------------

Variability in genotypic and allelic frequencies of *CYP2C9*, *CYP2C19*, and *MDR1* C3435T both between and within the MENA countries for which data were identified was not unexpected. Key factors contributing to this variability were likely small sample sizes and selective patient populations in whom many of the studies were conducted. The allelic frequencies of *CYP2C9\*2* and *\*3*, as well as *CYP2C19\*2* and *\*3* were comparable to those reported for Middle Eastern populations \[[@CR139], [@CR140]\]. Similar population data for the *MDR1* C3435T polymorphism were not available for comparison, nor were comparative data specific to North Africa populations.

Ethnicity significantly affects distributions of variants \[[@CR124]\] and contributes to differences in MAF reported for populations outside of the MENA region for each of *CYP2C9* \[[@CR48], [@CR50], [@CR53], [@CR57], [@CR65], [@CR67], [@CR70], [@CR139]\], *CYP2C19* \[[@CR27], [@CR53], [@CR57], [@CR67], [@CR140]\], and *MDR1* C3435T \[[@CR132], [@CR141], [@CR142]\]. This emphasizes the importance of population-specific studies assessing genetic polymorphisms.

Limitations {#Sec19}
-----------

This review has several limitations that must be considered when interpreting the results. Foremost, in the primary analysis, only three different countries within the MENA region were represented by study populations, with three of five studies being in subjects of Turkish origin. The genotypic diversity across MENA countries as well as the small sample size of the included studies, therefore limit the generalizability of this review. Moreover, only three of the five studies were conducted in patients with seizure disorder, of which only one assessed clinical outcomes, thereby limiting ability to make clinical inferences. The two healthy volunteer studies (which used data from the same subjects) were based on a single dose of phenytoin; therefore, they did not reflect the potential impact of genetic polymorphisms on the steady-state pharmacokinetics of phenytoin or the influence of the non-linear capacity-limited metabolism of phenytoin. Furthermore, all five studies had poor methodological quality and were likely not powered to compare differences between genotypes and alleles of relatively low frequencies. Regarding the review of genotypic and allelic frequencies, the small select study populations and resultant variability in frequency estimates limit generalizability.

Future Directions {#Sec20}
-----------------

Identified limitations of this review highlight the need for future studies to investigate the impact of genetic polymorphisms on the pharmacokinetics of phenytoin and associated clinical outcomes, specifically in patients with epilepsy and seizure disorders. Although the impacts of *CYP2C9\*2* and *\*3* allelic variants on phenytoin metabolism and the risk of adverse effects have been recognized and dosage modification guidelines developed \[[@CR8], [@CR9]\], the potential impacts of *CYP2C19\*2* and *\*3* allelic variants have not been established and warrant further investigation. Moreover, owing to the limitations of individual studies, the association between the *MDR1* C3435T genotype and drug-resistant epilepsy as well as phenytoin pharmacokinetics remains to be elucidated. To address these questions, future studies must be appropriately powered to assess differences between genotypes of low frequencies, and account for known confounding factors. Furthermore, studies should be designed to look at both pharmacokinetic and clinical outcomes once phenytoin concentrations have achieved a steady state. If possible, studies should be conducted in patient populations originating from countries of the MENA region that have not yet been assessed.

Future research may also focus on investigating the prevalence of the *HLA-B\*15:02* allele and its impact on the risk of phenytoin-induced severe cutaneous adverse reactions (i.e., Stevens--Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms) in populations originating within the MENA region. The presence of this allele has been associated with an increased risk of phenytoin-induced severe cutaneous adverse reactions \[[@CR38], [@CR143]--[@CR145]\], resulting in pharmacogenetic guidelines recommending against the use of phenytoin in patients who are *HLA-B\*15:02* carriers \[[@CR8]\].

Conclusion {#Sec21}
==========

Results of this review indicate the reduced functional capacities of *CYP2C9\*2* and *\*3* allelic variants significantly decrease phenytoin metabolism in patients originating from the MENA region. The impacts of *CYP2C19* and *MDR1* C3435T polymorphisms on phenytoin pharmacokinetics and clinical outcomes in this population are unclear and require further investigation. Future research should focus on better understanding the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy.

Appendix: MEDLINE search strategy {#Sec22}
=================================

MENA.mp.exp Africa, Northern/ or "Middle East and North Africa".mp. or exp Middle East/Afghanistan.mp. or exp Afghanistan/Bahrain.mp. or exp Bahrain/Djibouti.mp. or exp Djibouti/Egypt.mp. or exp Egypt/Algeria.mp. or exp Algeria/Iran.mp. or exp Iran/exp Iraq/ or Iraq.mp.Israel.mp. or exp Israel/Jordan.mp. or exp Jordan/Kuwait.mp. or exp Kuwait/Lebanon.mp. or exp Lebanon/Libya.mp. or exp Libya/Morocco.mp. or exp Morocco/Oman.mp. or exp Oman/Palestine.mp.West Bank.mp.Gaza.mp.Qatar.mp. or exp Qatar/Saudi Arabia.mp. or exp Saudi Arabia/Somalia.mp. or exp Somalia/exp South Sudan/ or exp Sudan/ or Sudan.mp.Syria.mp. or exp Syria/Tunisia.mp. or exp Tunisia/exp Turkey/ or Turkey.mp.United Arab Emirates.mp. or exp United Arab Emirates/Yemen.mp. or exp Yemen/1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28Polymorphism.mp. or exp Polymorphism, Genetic/ or exp Polymorphism, Single Nucleotide/Pharmacogenetics.mp. or exp Pharmacogenetics/Pharmacogenomics.mp.cytochrome p450.mp. or exp Cytochrome P-450 Enzyme System/CYP2C9.mp. or exp Cytochrome P-450 CYP2C9/CYP2C19.mp. or exp Cytochrome P-450 CYP2C19/CYP3A4.mp. or exp Cytochrome P-450 CYP3A/CYP2B6.mp. or exp Cytochrome P-450 CYP2B6/CYP1A2.mp. or exp Cytochrome P-450 CYP1A2/CYP2E1.mp. or exp Cytochrome P-450 CYP2E1/CYP2C8.mp. or exp Cytochrome P-450 CYP2C8/exp Cytochrome P-450 CYP2A6/ or CYP2A6.mp.exp Glucuronosyltransferase/ or UGT.mp.UGT1A1.mp.UGT1A4.mp.UGT1A6.mp.UGT1A9.mp.P-glycoprotein.mp. or exp P-Glycoprotein/multi drug resistance protein.mp. or exp Multidrug Resistance-Associated Proteins/ or exp ATP-Binding Cassette Transporters/exp P-Glycoproteins/ or exp P-Glycoprotein/ or MDR1.mp.ABCB1.mp.30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50phenytoin.mp. or exp Phenytoin/antiepileptic.mp. or exp Anticonvulsants/exp Epilepsy/ or epilepsy.mp.52 or 53 or 5429 and 51 and 55
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